Gattex vs Romvimza
A plain-English comparison of two other specialty drugs that may be accessible via NPP.
Side-by-side
| Gattex | Romvimza | |
|---|---|---|
| Generic name | teduglutide | vimseltinib |
| Manufacturer | Takeda Pharmaceuticals | Deciphera Pharmaceuticals (an Ono Pharmaceutical company) |
| Modality | Recombinant GLP-2 analog (daily subcutaneous injection) | Oral CSF1R tyrosine kinase inhibitor (30 mg twice weekly) |
| Indication | Gastroenterology (short bowel syndrome) | Oncology (tenosynovial giant cell tumor) |
| FDA approval | December 2012 (adults); May 2019 (pediatric 1+) | February 14, 2025 |
When physicians choose Gattex
Gattex is typically selected when its mechanism and labeled indication fit the disease subtype. It is manufactured by Takeda Pharmaceuticals and represents a Recombinant GLP-2 analog (daily subcutaneous injection) option in Gastroenterology (short bowel syndrome).
When physicians choose Romvimza
Romvimza is typically selected when its mechanism aligns better with disease sub-type, prior therapy failure, or safety profile. It is manufactured by Deciphera Pharmaceuticals (an Ono Pharmaceutical company) and represents an Oral CSF1R tyrosine kinase inhibitor (30 mg twice weekly) option in Oncology (tenosynovial giant cell tumor).
Both drugs - access via NPP
Both Gattex and Romvimza can be accessed via NPP in most of our covered markets. Choice between them is a clinical decision for the treating physician.
Not medical advice
This comparison is information, not clinical guidance.
Request either drug
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).